Form 4: Odyssey Health, Inc. Reduces Stake in Oragenics Inc. Through Recent Stock Sales

Odyssey Health, Inc., a 10% owner and director of Oragenics Inc. (OGEN), reported the sale of 10,000 shares of common stock across two transactions in mid-June 2025.

Summary

• Odyssey Health, Inc., identified as both a Director and a 10% Owner of Oragenics Inc. (OGEN), filed a Form 4 statement.
• The filing details two separate sales of Oragenics Inc. common stock.
• On June 13, 2025, Odyssey Health, Inc. sold 5,000 shares of OGEN common stock at a price of $4.27 per share.
• Following this transaction, Odyssey Health, Inc. beneficially owned 12,044 shares of OGEN common stock.
• On June 16, 2025, an additional 5,000 shares of OGEN common stock were sold at a price of $4.45 per share.
• After both reported transactions, Odyssey Health, Inc.'s beneficial ownership in Oragenics Inc. stands at 7,044 shares.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to the insider selling by a significant owner and director. While the amounts are not massive, any reduction in stake by a key insider can be viewed unfavorably by the market, suggesting a potential lack of confidence or a decision to reallocate capital away from the company.

Negatives

• A significant shareholder and director, Odyssey Health, Inc., reduced its stake in Oragenics Inc. by selling a total of 10,000 shares.
• Insider selling can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects.

Risks

• Potential negative market perception due to insider selling by a 10% owner and director.
• Reduced alignment of interests between the reporting person and other shareholders due to decreased ownership.

Future Outlook

The document is a Form 4 reporting past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reflects an individual insider's trading activity and does not inherently provide broader industry context. However, significant insider selling across an industry can sometimes signal a general downturn or specific challenges within that sector. In isolation, this filing primarily impacts the specific company, Oragenics Inc., and its investor sentiment.

Comparison to Industry Standards

• This document reports specific insider trading activity for Oragenics Inc. and does not provide sufficient information to compare its financial results or operational performance against global industry benchmarks or specific comparable companies/projects. Insider trading patterns vary widely and are not typically used for direct industry-wide performance comparisons.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially impacting investor confidence and the stock price.

Key Dates

Recommendation

Keywords

Oragenics Inc., OGEN, Odyssey Health Inc., SEC Form 4, Insider Selling, Beneficial Ownership, Stock Sale, Corporate Governance, Director, 10% Owner